There have been over 200 clinical trials conducted related to Mesothelioma.
Mesothelioma Clinical trials are research studies completed with the help of human volunteers, Mesothelioma doctors, Mesothelioma researchers, and drug companies to test the effectiveness of various Mesothelioma treatments.
Mesothelioma drugs being studied include, Alimta (Pemetrexed), Avastin, Axitinib, Cisplatin, Glivec, Gemzar, Bortezomib, Milataxel, Everolimus, Velcade, Dasatinib, Sunitinib Malate, Capecitabine and Veglin.
Mesothelioma clinical trials allow doctors to access new levels of treatment for the disease and provide alternative treatment options to some Mesothelioma patients.
Our nationwide toll-free number to get help is (888) 291-0963
Mesothelioma Clinical Trials
Mesothelioma clinical trials test large groups of people between 1,000 and 3,000 patients.
Each Mesothelioma clinical trial has qualifications and guidelines that determine the eligibility of participants.
Some Mesothelioma clinical trials are research studies designed to find improved ways to prevent, diagnose, and treat malignant Mesothelioma.
Mesothelioma clinical trials are being conducted throughout the world, examining new drugs, radiation & chemotherapy techniques, and combined modality treatments.
Some Mesothelioma clinical trials include Intensity Modulated Radiation Therapy and Helical Tomotherapy Treatment.
Some Mesothelioma clinical trials include Gene therapy and vaccine therapy.
Some Mesothelioma clinical trials require Mesothelioma patients who have not been treated at all.
The National Cancer Institute sponsors 14 Mesothelioma clinical trials that are designed to find new treatments and better ways to use current treatments.
Mesothelioma clinical studies report that the average time to disease progression after treatment is 14.4 months.
Mesothelioma clinical studies report that the average overall survival time is 15.5 months.
Mesothelioma Clinical Trials – Phase 1-4
Mesothelioma clinical trials are measured in 4 primary phases. These 4 phases help determine when a particular Mesothelioma treatment is tested for safety, effectiveness if it is better than a current cure.
Phase I Mesothelioma Clinical Trials
- Establishes the process for administering of treatment regimen and amount of drug dosage.
- Trials test small groups of people between 20-80 Mesothelioma patients.
Phase II Mesothelioma Clinical Trials
- Tests Drug effectiveness
- Tests Drug safety and efficacy.
Phase III Mesothelioma Clinical Trials
- Tests a larger group of people between 100-300 Mesothelioma patients.
- Tests the effectiveness of treatment and evaluates its overall safety.
- Tests drug effectiveness compared against existing treatments.
Phase IV Mesothelioma Clinical Trials
- Tests to examine potential side effects and risks over a more extended period.
- The test may be conducted as a post-approval study to gather any additional information.
If a treatment passes through all three phases, it receives final approval by the FDA for public use.
Other Mesothelioma Clinical Trial Guidelines
Mesothelioma researchers refer to these guidelines as inclusion and exclusion criteria.
Inclusion criteria- Factors that allow a Mesothelioma patient to participate.
Exclusion criteria- Factors that prevent a patient from entering a clinical trial.
Inclusion and Exclusion criteria for Mesothelioma clinical trials can be based on the following:
- Age of patient
- Gender of patient
- Overall physical health of patient
- Patients’ treatment history
- Type and stage of the Mesothelioma cancer